tetracontane-1,40-diol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: tetracontane-1,40-diol
• 化学式: C₄₀H₈₂O₂
• 分子量: 595.09
• InChiKey: CNADWWDQQLFROG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  18.7
• 重原子数：
  42
• 可旋转键数：
  39
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tetracontane-1,40-diol 、 硬脂酸 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs

  摘要：

  Designing feasible and effective peptide ligand modified solid lipid nanoparticles (SLNs) to improve oral bioavailability of protein drugs and evaluating the influence of mucus remains important. In the present work, two kinds of peptide ligand modified SLNs loaded with salmon calcitonin (sCT), namely, sCT CSK-SLNs and sCT IRQ-SLNs, were prepared by coupling the peptide ligand CSKSSDYQC (CSK) which was reported to show affinity with goblet cells, or IRQRRRR (IRQ), a cell penetrating peptide, to polyoxyethylene (40) stearate (SA-PEC2000). Compared with unmodified SLNs, CSK or IRQ modified SLNs with better drug protection ability could facilitate the internalization of drug on Caco-2/HT29-MTX co-cultured cells and permeation in excised rat duodenum mucosa. The internalization mechanism of two kinds of peptide ligand modified SLNs was mainly active transport via both clathrin- and caveolae-dependent endocytosis. Although mucus was an impediment to the transport of SLNs, the peptide ligand modified SLNs still showed improved drug absorption. The absolute bioavailability of sCT CSK-SLNs (12.41 +/- 3.65%) and sCT IRQ-SLNs (10.05 +/- 5.10%) raised to 2.45-fold and 1.98-fold compared with unmodified SLNs (5.07 +/- 0.54%), implying the feasibility and effectiveness of CSK and IRQ peptide modification for the enhancement of the oral bioavailability of protein drugs. In summary, the nanoparticles modified with CSK or IRQ peptide ligand could be the potential carriers for the transport of protein drugs across intestinal barriers. (C) 2014 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ejpb.2014.06.011

文献信息

• VITAMIN C PREPARATION
  申请人：Perez Pedro P.

  公开号：US20080207748A1

  公开（公告）日：2008-08-28

  The present invention relates to vitamin C preparations which enhance absorption of vitamin C into cells, and prolong the retention of vitamin C within the blood plasma and tissue of mammals, such as humans. The vitamin C preparations of the present invention include lipophilic molecules which improve the absorption of vitamin C resulting in higher plasma and cellular levels.
• PLANT EXTRACTS FROM ACRONYCHIA SPECIES AND THEIR USE
  申请人：Gordon Victoria Anne

  公开号：US20110318439A1

  公开（公告）日：2011-12-29

  The invention relates to plant extracts and bioactive molecules derived from the plant genus Acronychia and their use as antioxidants, antibacterials, anthelmintic, anti-inflammatories, cancer chemopreventatives, food additives and fragrance components in pharmaceuticals, nutraceuticals, foods and cosmetics.
• PHYTOCANNABINOID FORMULATIONS AND METHODS FOR EXTRACTION
  申请人：Perez Pedro P.

  公开号：US20210106555A1

  公开（公告）日：2021-04-15

  A phytocannabinoid formulation comprises an amount of at least about 90 percent by weight of one or more phytocannabinoid. The phytocannabinoid formulation further comprises an amount of at least about 0.1 percent by weight of a plurality of lipophilic molecules including at least one saturated straight chain C 14 -C 20 fatty acid and at least one unsaturated ω-6 C 18 -C 22 fatty acid. The phytocannabinoid formulation also includes an amount of at least about 0.1 percent by weight of at least one bioflavonoid.
• US9220928B2
  申请人：——

  公开号：US9220928B2

  公开（公告）日：2015-12-29
• [EN] PHYTOCANNABINOID FORMULATIONS AND METHODS FOR EXTRACTION<br/>[FR] FORMULATIONS DE PHYTOCANNABINOÏDES ET PROCÉDÉS D'EXTRACTION
  申请人：PEREZ PEDRO P

  公开号：WO2021076562A1

  公开（公告）日：2021-04-22

  A phytocannabinoid formulation comprises an amount of at least about 90 percent by weight of one or more phytocannabinoid. The phytocannabinoid formulation further comprises an amount of at least about 0.1 percent by weight of a plurality of lipophilic molecules including at least one saturated straight chain C14-C20 fatty acid and at least one unsaturated ω-6 C18-C22 fatty acid. The phytocannabinoid formulation also includes an amount of at least about 0.1 percent by weight of at least one bioflavonoid.